Publications by authors named "F Pages"
Background: Tumor Budding (TB) and Immunoscore are independent prognostic markers in colon cancer (CC). Given their respective representation of tumor aggressiveness and immune response, we examined their combination in association with patient disease-free survival (DFS) in pTNM stage I-III CC.
Methods: In a series of pTNM stage I-III CCs (n = 654), the Immunoscore was computed and TB detected automatically using a deep learning network.
Purpose: Immunoscore (IS) is prognostic in stage III colorectal cancer (CRC) and may predict benefit of duration (6 3 months) of adjuvant infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. We sought to determine IS prognostic and predictive value in stage-III CRC treated with adjuvant FOLFOX or oral capecitabine and infusional oxaliplatin (CAPOX) in the SCOT and IDEA-HORG trials.
Methods: Three thousand sixty-one cases had tumor samples, of which 2,643 (1,792 CAPOX) were eligible for IS testing.
Article Synopsis
- The study aimed to evaluate the Immunoscore (IS) as a potential biomarker for patients with rectal cancer managed by a watch-and-wait (W&W) strategy, focusing on predicting recurrence after treatment.
- It involved 249 patients and analyzed the presence of specific immune cells in pre-treatment biopsies, finding that higher IS scores were associated with better 5-year recurrence-free rates.
- The results indicate that IS is a strong independent predictor of time to recurrence and improves the accuracy of clinical models in assessing patient outcomes.
Background: The Immunoscore (IS) is a quantitative digital pathology assay that evaluates the immune response in cancer patients. This study reports on the reproducibility of pathologists' visual assessment of CD3+- and CD8+-stained colon tumors, compared to IS quantification.
Methods: An international group of expert pathologists evaluated 540 images from 270 randomly selected colon cancer (CC) cases.